EUVIMEDEUVIMED entdecken
Crossref

Exercising and immuno-oncology treatment (ExIO): a prospective pilot study for patients with solid tumors

Paulo Gustavo Bergerot, Cristiane Decat Bergerot, Jonas Ribeiro Gomes Silva, William Hiromi Fuzita, Marcos V S Franca, Paulo Sergio Lages, Gabriel Dos Anjos, Andressa Cardoso de Azeredo, Carolina Bezerra Patriota, Marco Murilo Buso, João Nunes Matos Neto, David Lee und 5 weitere

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-09056-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Paulo Gustavo Bergerot und 16 weiteren Autor:innen. Beteiligte Einrichtung: Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Av. Pres. Juscelino Kubitschek, 510, 2º Andar, Itaim Bibi, Sao Paulo, SP, Brazil. pau…. Hauptthemen laut MEDLINE: Neoplasms, Quality of Life, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Despite exercise's known benefits for cancer patients, little is understood about combining it with immune checkpoint inhibitors (ICI). This study aims to assess the feasibility and acceptability of a personalized physical activity program for cancer patients on ICI treatment and to investigate its effects on quality of life, ICI-related side effects, fatigue, and emotional symptoms. METHODS: This prospective study was conducted across eight cancer practices in a joint network in Brazil. Eligible cancer patients undergoing ICIs were recruited from June 2022 to January 2023. Participants completed a 12-week physical activity program with remote supervision. Baseline and 12-week assessments utilized the FACT-ICM, BFI, ESAS, PROMIS-Anxiety, and FCR-7 scales. Feasibility and acceptability were evaluated based on enrollment, retention, and adherence rates, with patient feedback collected at week 12. Linear mixed models were employed to assess outcomes. RESULTS: Out of 38 patients, 81% showed high adherence, 62% engaged in activities more than 4 days weekly, and 97% were satisfied with the program. The sample was mostly female (55%), median age of 60.5, primarily diagnosed with breast cancer (26%) and renal cell carcinoma (24%), with 60.5% having metastatic cancer. Sixty percent received ICI combined with chemotherapy. Significant improvements were observed over time in treatment-related side effects, emotional symptoms, and quality of life (p < 0.001). CONCLUSION: These findings endorse integrating an exercise program with remote supervision into the care of cancer patients undergoing ICI treatment. This intervention may positively impact symptom management and quality of life, offering a cost-effective approach in oncologic treatment and survivorship care globally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsQuality of LifeImmune Checkpoint InhibitorsHumansPilot ProjectsFemaleProspective StudiesMaleMiddle AgedAgedBrazilFatigueExercise TherapyFeasibility StudiesExerciseAdult

Stichwörter der Autor:innen

CancerExerciseOncologyPhysical activity

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Av. Pres. Juscelino Kubitschek, 510, 2º Andar, Itaim Bibi, Sao Paulo, SP, Brazil. paulobergerot@gmail.com.
  • Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Av. Pres. Juscelino Kubitschek, 510, 2º Andar, Itaim Bibi, Sao Paulo, SP, Brazil.
  • University of New Mexico, Albuquerque, NM, USA.
  • University of California Los Angeles, Los Angeles, CA, USA.
  • University of Pittsburgh, Pittsburgh, PA, USA.
  • City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Zitieren

APA

Bergerot, P. G., Bergerot, C. D., Silva, J. R. G., Fuzita, W. H., Franca, M. V. S., Lages, P. S., Dos Anjos, G., de Azeredo, A. C., Patriota, C. B., Buso, M. M., Matos Neto, J. N., Lee, D., Philip, E. J., Schmitz, K. H., Pal, S. K., Soto-Pérez-de-Celis, E., & Florez, N. (2024). Exercising and immuno-oncology treatment (ExIO): a prospective pilot study for patients with solid tumors. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-09056-3

Vancouver

Bergerot PG, Bergerot CD, Silva JRG, Fuzita WH, Franca MVS, Lages PS, et al. Exercising and immuno-oncology treatment (ExIO): a prospective pilot study for patients with solid tumors. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-09056-3

BibTeX
@article{Bergerot2024,
  author = {Bergerot, Paulo Gustavo and Bergerot, Cristiane Decat and Silva, Jonas Ribeiro Gomes and Fuzita, William Hiromi and Franca, Marcos V S and Lages, Paulo Sergio and Dos Anjos, Gabriel and de Azeredo, Andressa Cardoso and Patriota, Carolina Bezerra and Buso, Marco Murilo and Matos Neto, João Nunes and Lee, David and Philip, Errol J and Schmitz, Kathryn H and Pal, Sumanta K and Soto-Pérez-de-Celis, Enrique and Florez, Narjust},
  title = {Exercising and immuno-oncology treatment (ExIO): a prospective pilot study for patients with solid tumors},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-09056-3}
}
Kostenlos starten →